Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Arsenic trioxide and neuroblastoma cytotoxicity.

  • Helen Pettersson
  • Jenny Karlsson
  • Alexander Pietras
  • Ingrid Øra
  • Sven Påhlman
Publishing year: 2007
Language: English
Pages: 35-41
Publication/Series: Journal of Bioenergetics and Biomembranes
Volume: 39
Issue: 1
Document type: Journal article review
Publisher: Kluwer

Abstract english

The majority of aggressive forms of the childhood tumor neuroblastoma can with current treatment protocols not be cured and possess a major challenge in pediatric oncology. After initial rounds of chemotherapy, surgery and irradiation, which in most cases result in tumor regression, these aggressive neuroblastomas relapse and frequently develop drug resistance. As approximately 50% of the children with neuroblastoma have an aggressive form, there is a compelling demand for new treatment strategies. Arsenic trioxide has the capacity to kill multidrug-resistant neuro-blastoma cells in vitro and in vivo and the drug is currently being evaluated in clinical trials. In this report we discuss the background to the use of arsenic trioxide in cancer therapy and the currently known mechanisms by which arsenic trioxide kills human neuroblastoma cells.


  • Cancer and Oncology
  • Pediatrics
  • Neuroblastoma
  • Arsenic trioxide
  • Cell death
  • APL
  • Bax


  • ISSN: 1573-6881
Sven Påhlman
E-mail: sven [dot] pahlman [at] med [dot] lu [dot] se


Division of Translational Cancer Research

+46 46 222 64 21

MV406 312K1